vs
RCM TECHNOLOGIES, INC.（RCMT）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是RCM TECHNOLOGIES, INC.的1.5倍（$127.1M vs $86.5M），再鼎医药同比增速更快（17.1% vs 12.4%），过去两年再鼎医药的营收复合增速更高（20.8% vs 9.6%）
埃克塞拉科技是一家美国业务流程自动化企业，由SourceHOV、Novitex Holdings与Quinpario Acquisition Corp. 2合并组建，专注为各行业客户提供自动化业务解决方案，助力企业优化运营流程、提升运转效率。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
RCMT vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.5倍
$86.5M
营收增速更快
ZLAB
高出4.7%
12.4%
两年增速更快
ZLAB
近两年复合增速
9.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $86.5M | $127.1M |
| 净利润 | $6.1M | — |
| 毛利率 | 28.1% | 51.0% |
| 营业利润率 | 9.2% | -54.6% |
| 净利率 | 7.1% | — |
| 营收同比 | 12.4% | 17.1% |
| 净利润同比 | 112.9% | — |
| 每股收益（稀释后） | $0.80 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RCMTZLAB
| Q1 26 | $86.5M | — | ||
| Q4 25 | — | $127.1M | ||
| Q3 25 | $70.3M | $115.4M | ||
| Q2 25 | $78.2M | $109.1M | ||
| Q1 25 | $84.5M | $105.7M | ||
| Q4 24 | $76.9M | $108.5M | ||
| Q3 24 | $60.4M | $101.8M | ||
| Q2 24 | $69.2M | $100.1M |
净利润RCMTZLAB
| Q1 26 | $6.1M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $2.3M | $-36.0M | ||
| Q2 25 | $3.8M | $-40.7M | ||
| Q1 25 | $4.2M | $-48.4M | ||
| Q4 24 | $2.9M | — | ||
| Q3 24 | $2.7M | $-41.7M | ||
| Q2 24 | $3.8M | $-80.3M |
毛利率RCMTZLAB
| Q1 26 | 28.1% | — | ||
| Q4 25 | — | 51.0% | ||
| Q3 25 | 27.6% | 59.5% | ||
| Q2 25 | 28.5% | 60.6% | ||
| Q1 25 | 26.0% | 63.6% | ||
| Q4 24 | 28.0% | 61.5% | ||
| Q3 24 | 29.6% | 64.1% | ||
| Q2 24 | 28.9% | 64.9% |
营业利润率RCMTZLAB
| Q1 26 | 9.2% | — | ||
| Q4 25 | — | -54.6% | ||
| Q3 25 | 5.6% | -42.3% | ||
| Q2 25 | 8.4% | -50.3% | ||
| Q1 25 | 7.8% | -53.3% | ||
| Q4 24 | 8.2% | -62.6% | ||
| Q3 24 | 7.3% | -66.6% | ||
| Q2 24 | 8.4% | -76.0% |
净利率RCMTZLAB
| Q1 26 | 7.1% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 3.2% | -31.2% | ||
| Q2 25 | 4.8% | -37.3% | ||
| Q1 25 | 5.0% | -45.8% | ||
| Q4 24 | 3.7% | — | ||
| Q3 24 | 4.5% | -40.9% | ||
| Q2 24 | 5.4% | -80.2% |
每股收益（稀释后）RCMTZLAB
| Q1 26 | $0.80 | — | ||
| Q4 25 | — | $-0.05 | ||
| Q3 25 | $0.30 | $-0.03 | ||
| Q2 25 | $0.50 | $-0.04 | ||
| Q1 25 | $0.54 | $-0.04 | ||
| Q4 24 | $0.38 | $-0.09 | ||
| Q3 24 | $0.35 | $-0.04 | ||
| Q2 24 | $0.47 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.9M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $46.0M | $715.5M |
| 总资产 | $134.4M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RCMTZLAB
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $689.6M | ||
| Q3 25 | $1.3M | $717.2M | ||
| Q2 25 | $5.5M | $732.2M | ||
| Q1 25 | $5.2M | $757.3M | ||
| Q4 24 | $4.7M | $779.7M | ||
| Q3 24 | $3.2M | $616.1M | ||
| Q2 24 | $3.5M | $630.0M |
股东权益RCMTZLAB
| Q1 26 | $46.0M | — | ||
| Q4 25 | — | $715.5M | ||
| Q3 25 | $41.4M | $759.9M | ||
| Q2 25 | $37.8M | $791.7M | ||
| Q1 25 | $34.6M | $810.8M | ||
| Q4 24 | $33.5M | $840.9M | ||
| Q3 24 | $30.0M | $667.7M | ||
| Q2 24 | $28.5M | $704.2M |
总资产RCMTZLAB
| Q1 26 | $134.4M | — | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | $129.8M | $1.2B | ||
| Q2 25 | $135.6M | $1.2B | ||
| Q1 25 | $121.0M | $1.2B | ||
| Q4 24 | $132.1M | $1.2B | ||
| Q3 24 | $125.5M | $985.3M | ||
| Q2 24 | $118.3M | $987.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.0M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 3.11× | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流RCMTZLAB
| Q1 26 | $19.0M | — | ||
| Q4 25 | — | $-26.0M | ||
| Q3 25 | $-1.3M | $-32.0M | ||
| Q2 25 | $-7.9M | $-31.0M | ||
| Q1 25 | $16.7M | $-61.7M | ||
| Q4 24 | $-1.6M | $-55.8M | ||
| Q3 24 | $-4.3M | $-26.8M | ||
| Q2 24 | $5.7M | $-42.2M |
自由现金流RCMTZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | $-26.7M | ||
| Q3 25 | $-1.8M | $-35.0M | ||
| Q2 25 | $-8.4M | $-33.9M | ||
| Q1 25 | $16.2M | $-63.2M | ||
| Q4 24 | $-2.6M | $-58.4M | ||
| Q3 24 | $-4.9M | $-28.2M | ||
| Q2 24 | $5.3M | $-42.9M |
自由现金流率RCMTZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | -21.0% | ||
| Q3 25 | -2.5% | -30.4% | ||
| Q2 25 | -10.7% | -31.1% | ||
| Q1 25 | 19.2% | -59.9% | ||
| Q4 24 | -3.4% | -53.8% | ||
| Q3 24 | -8.1% | -27.7% | ||
| Q2 24 | 7.7% | -42.9% |
资本支出强度RCMTZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | 0.7% | 2.6% | ||
| Q2 25 | 0.6% | 2.6% | ||
| Q1 25 | 0.5% | 1.5% | ||
| Q4 24 | 1.3% | 2.4% | ||
| Q3 24 | 0.9% | 1.3% | ||
| Q2 24 | 0.6% | 0.7% |
现金转化率RCMTZLAB
| Q1 26 | 3.11× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -0.56× | — | ||
| Q2 25 | -2.08× | — | ||
| Q1 25 | 3.98× | — | ||
| Q4 24 | -0.57× | — | ||
| Q3 24 | -1.58× | — | ||
| Q2 24 | 1.52× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RCMT
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
